SANA logo

Sana Biotechnology Inc. (SANA)

$1.88

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SANA

Market cap

$563313708

EPS

-0.52

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

2.304731

Price on SANA

Previous close

$2.02

Today's open

$1.99

Day's range

$1.87 - $2.02

52 week range

$1.86 - $5.49

Profile about SANA

CEO

Steven D. Harr

Employees

142

Headquarters

Seattle, WA

Exchange

Nasdaq Global Select

Shares outstanding

299634951

Issue type

Common Stock

SANA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on SANA

Bears are Losing Control Over Sana (SANA), Here's Why It's a 'Buy' Now

Sana (SANA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

news source

Zacks Investment Research • Nov 16, 2026

news preview

2 healthcare stocks to turn $10 into $100 by next year

Healthcare stocks have emerged as an area of relative strength in 2026, outperforming technology shares as investors seek opportunities beyond the artificial intelligence (AI) boom.

news source

Finbold • Nov 11, 2026

news preview

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet cell transplantation with UP421 without immunosuppression in type 1 diabetes Advancing strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress with SG227, a CD8-targeted fusosome that delivers to CD8+ T cells the genetic material to make BCMA-directed CAR T cells, as a potential treatment for patients with multiple myeloma; expect to begin clinical study as early as 2027 Q3 2026 cash position of $121.7 million; expected cash runway into mid-2027 SEATTLE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the third quarter 2026. “We continue to make meaningful progress toward initiating clinical studies of SC451 later this year and SG293 in 1Q 2027,” said Steve Harr, Sana's President and Chief Executive Officer.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Sana Biotechnology: A Shot At Diabetes

Sana Biotechnology trades at a steep discount despite promising T1D assets UP421 and SC451. UP421 demonstrated durable insulin production without immunosuppression in early data, positioning SANA as a potential T1D disruptor. Cash runway is limited to 5 quarters at the current burn, making Sana dependent on the near-term success of their pipeline.

news source

Seeking Alpha • Oct 13, 2026

news preview

Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 15, 2026

news preview

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

news source

Seeking Alpha • Sep 10, 2026

news preview

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

news source

Seeking Alpha • Sep 10, 2026

news preview

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

news source

PRNewsWire • Sep 7, 2026

news preview

Sana Biotechnology to Present at September 2026 Investor Conferences

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update.

news source

GlobeNewsWire • Sep 1, 2026

news preview

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

news source

Zacks Investment Research • Jul 20, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Sana Biotechnology Inc.

Open an M1 investment account to buy and sell Sana Biotechnology Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SANA on M1